Navigation Links
Cynosure Reports Record Revenues for Fourth-Quarter and Full-Year 2012
Date:2/12/2013

ash and equivalents, and we have no long-term debt. We believe our financial resources position us well for the future, and provide us with increased ability to consider promising opportunities that fit the criteria of our growth strategy."

Recent Highlights

  • In November 2012, the Company completed the public offering of 3,680,000 shares of class A common stock, which included 840,000 shares from selling stockholder El.En. S.p.A. The offering resulted in net proceeds of approximately $55.3 million to the Company.
  • The Company announced on December 4, 2012 that it received 510(k) clearance from the U.S. Food and Drug Administration to market the PicoSure™ laser workstation for the removal of tattoos and benign pigmented lesions. The Company expects to sell PicoSure initially through its U.S. direct sales force to aesthetic dermatologists and plastic surgeons. The Company plans to launch PicoSure in March 2013 at the Annual Meeting of the American Academy of Dermatology.
  • Business Outlook 
    "We capped a successful 2012 with our fifth consecutive quarter of profitability and record revenue on both a quarterly and full-year basis," Davin said. "We believe we enter 2013 poised for another year of profitable growth. We are excited for the launch of our newest flagship device, PicoSure, for the removal of tattoos and benign pigmented lesions.  After nearly a decade of research and development, this device provides us with a first-mover advantage in a large and underserved market. In addition, we expect that Cynosure's first home-use device, developed in partnership with Unilever, for the treatment of facial wrinkles will be commercially launched by Unilever in 2013." 

    Fourth-Quarter Financial Results Conference CallIn conjunction with the announcement of its fourth-quarter and year-end 2012 financial results, Cynosure will host a conference call for investors and an
    '/>"/>

    SOURCE Cynosure, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Cynosure Receives FDA Clearance for At-Home Device for the Treatment of Wrinkles
    2. Cynosure Announces Upcoming Conference Presentations
    3. Cynosure, Inc. Announces Proposed Public Offering of Class A Common Stock
    4. Cynosure, Inc. Prices Public Offering of Class A Common Stock
    5. Cynosure to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
    6. Cynosure to Host Fourth-Quarter 2012 Financial Results Conference Call on February 12
    7. Cynosure to Participate in Leerink Swann Global Healthcare Conference 2013
    8. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    9. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    10. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
    11. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/21/2014)... and MELVILLE, N.Y. , Nov. ... CAH ), one of the world,s largest health care ... HSIC ), the world,s largest provider of health care ... medical practitioners, today announced that the companies have entered ... the most comprehensive service and product offerings to office-based ...
    (Date:11/21/2014)... 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) announced ... will be presenting at the 26 th Annual Piper ... New York . The formal presentation is ... In addition, Mr. Krakauer and Jorgen B. Hansen , ... during the day. An audio webcast will ...
    (Date:11/21/2014)...  The acceptance of two abstracts on the ... demonstrates continued interest in the Eclipse System, the ... of the abstracts, presented by Catherine Matthews ... Urogynecology and Reconstructive Pelvic Surgery at the University ... Written Abstract on Urogynecology/Pelvic Floor Disorders/Vaginal Surgery. ...
    Breaking Medicine Technology:Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3
    ... Nov. 18 Starpharma Holdings Limited (ASX: SPL; OTCQX: ... of A$15.6 million through a private placement to institutional ... approximately A$24 million. , The lead investor in the ... highly regarded institutional fund manager. As a result ...
    ... , SAN DIEGO, Nov. 18 Rules-Based Medicine, Inc. ... and services agreement with Covance Inc. (NYSE: CVD ... powerful combination of biomarker technologies and services for use in ... RBM as its exclusive third-party provider of multiplexed protein biomarker ...
    Cached Medicine Technology:Starpharma Announces $15.6 million Capital Raising 2Starpharma Announces $15.6 million Capital Raising 3Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 2Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 3
    (Date:11/22/2014)... 2014 PrettyTailor , an outstanding ... new big promotion. Customers can buy new dresses at ... can visit its website. , As a matter of ... dresses. It mainly provides four types of wedding outfits, ... flower girl dresses. It also provides a variety of ...
    (Date:11/22/2014)... Today, Dylan Queen, a renowned brand in ... dresses; the business offers a wide range of special ... worldwide, allowing them to create multiple looks easily. , ... new collection of chic wedding dresses has been prepared ... at discounted rates now. Dylan Queen can always create ...
    (Date:11/22/2014)... 2014 Nocturia is defined by ... that the individual has to wake at night ... “Nocturia – Pipeline Review, H2 2014” provides comprehensive ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ...
    (Date:11/22/2014)... November 22, 2014 The topic of ... of block retaining walls. The article states that, “While they ... several necessary steps that go into creating this powerful look.” ... a retaining wall is choosing which kind of block matches ... , B&D Rockeries says, “The two main options are concrete ...
    (Date:11/22/2014)... FL (PRWEB) November 22, 2014 ... Innovations are pleased to announce that Ashley Lombardo ... Thanksgiving #PayItForward contest. , Ms. Lombardo entered friend ... Kitchen Innovations. She wrote of how her friend is ... daughters as a single mom. Despite medical bills piling ...
    Breaking Medicine News(10 mins):Health News:Customers Are Welcome to Shop at PrettyTailor.com 2Health News:Dylan Queen Introduces Its New Wedding Dresses 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2Health News:Forbes Living TV Announces Winner of Thanksgiving #PayItForward Contest 2
    ... -- Tiens Biotech Group (USA), Inc.,(the "Company" or "Tiens", ... financial results for the twelve months ended,December 31, 2008. ... ended December 31, 2008, revenue was $77.2 million,an increase ... months ended,December 31, 2007. , ...
    ... in trial;, ... data to be available in one year-,BELLEVILLE, ON, ... (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, ... its initial Phase III registration trial evaluating Urocidin(TM) ...
    ... ANN ARBOR, Mich., March 31 Thomson Reuters today ... costs by $4 billion over three years while improving ... Billion campaign will offer U.S. hospital CEOs an ... norms and benchmarks in clinical quality, patient safety, financial ...
    ... across North Carolina , ... Englewood, CO (Vocus) March ... science careers and information, unveiled the seventh edition of the ... ,This regional campaign is a promotional effort highlighting biotechnological, pharmaceutical and ...
    ... advances in pain management techniques, patients suffering from chronic or intense pain ... ... Singapore (PRWEB) March 31, 2009 -- With advances in pain management ... to grit their teeth and bear it., , , , ,"In any ...
    ... numerous CT scans over their lifetime may be at increased ... April issue of Radiology . , "We found that ... of the patients in our study had enough recurrent CT ... or more above baseline levels," said Aaron Sodickson, M.D., Ph.D., ...
    Cached Medicine News:Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 2Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 3Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 4Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 5Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 6Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 7Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 8Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 9Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 10Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 11Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 12Health News:Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM) 2Health News:Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM) 3Health News:Thomson Reuters Launches Campaign to Reduce Healthcare Costs by $4 Billion 2Health News:Thomson Reuters Launches Campaign to Reduce Healthcare Costs by $4 Billion 3Health News:BioSpace Launches the 2009 Bio NC™ Hotbed Campaign 2Health News:SingaporeMedicine Highlights Singapore's Advanced Pain Management Techniques 2Health News:SingaporeMedicine Highlights Singapore's Advanced Pain Management Techniques 3Health News:SingaporeMedicine Highlights Singapore's Advanced Pain Management Techniques 4Health News:CT scans: Too much of a good thing can be risky 2
    Bookler Richardson Blade Set - for use with Bookler Universal Table Mounted Retractor Systems...
    Richardson Retractors...
    A full, rounded look that adds greater dimension to the breast. Moderate base, with a higher profile than our Style 1600 implant....
    Inquire...
    Medicine Products: